Enzyme News and Research

RSS

High blood pressure drugs found to be safe for COVID-19 patients

Despite concerns expressed by some experts, common high blood pressure drugs did not increase the risk of contracting COVID-19 - or of developing severe disease - in a study of 12,594 patients.

3 May 2020

AHA awards grants to 12 teams for fast-tracked heart and brain health research related to COVID-19

Less than a month after issuing a rapid response call for scientific research proposals for fast-tracked studies of the effects of COVID-19 on the body's cardiovascular and cerebrovascular systems, the American Heart Association has awarded $1.2 million in grants to teams at 12 institutions across the U.S. to begin this unprecedented work.

2 May 2020

UBC discovery could pave way for developing new anti-malarial drugs

For the first time, UBC researchers have shown a key difference in the three-dimensional structures of a key metabolic enzyme in the parasite that causes malaria compared to its human counterpart.

2 May 2020

An extended SAR analysis of lipophilic guanylhydrazone analogues as promising trypanocidal agents

Sleeping sickness and Chagas disease, caused by the tropical parasites Trypanosoma brucei and Trypanosoma cruzi, constitute a significant socioeconomic burden in low-income countries of sub-Saharan Africa and Latin America, respectively.

2 May 2020

Scientists generate molecular models of compounds relevant for COVID-19

The discovery of suitable drugs that could help treat diseases is a long process. However, computer-aided drug design and simulation could speed up the process and also increase the possibilities say experts. This form of drug design and simulation could soon be the gold standard in drug development.

30 Apr 2020

New database catalogs peptides that may halt SARS-CoV-2 cell infection

In the quest for a highly specific and tailored treatment strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recent publication available on the preprint server bioRxiv describes a repository of designed peptides that interfere with the early stages of viral invasion process.

30 Apr 2020

Fear of coronavirus propels some smokers to quit

In 40 years of smoking, Katie Kennedy has tried four times to quit but always went back to cigarettes. Today, she is summoning a new mental image when a craving comes on: rows of COVID-19 patients hooked to ventilators.

30 Apr 2020

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

Remdesivir is an antiviral first developed by Gilead in 2014 as a treatment for Ebola and Marburg viruses. However, scientists explored its possibilities as a broad-spectrum drug when it proved effective against SARS-CoV and MERS-CoV, coronaviruses which were responsible for earlier outbreaks.

30 Apr 2020

Radboudumc researchers find essential mechanism in the disease process of COVID-19

Researchers at the Radboud University Medical Center seem to have found an essential mechanism in the disease process of COVID-19, which has so far been overlooked.

29 Apr 2020

ACE inhibitors appear to be safe and beneficial for COVID-19, say researchers

Researchers in India have conducted a meta-analysis investigating the effects of using angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on outcomes among patients with COVID-19.

29 Apr 2020

Tobacco use may explain why more men die of coronavirus than women in Spain

Whether or not you are a smoker could condition how the coronavirus affects you. At least that is what numerous researchers are saying, insisting that tobacco use is to blame for the weakened cardiovascular systems which are at greatest risk from COVID-19.

29 Apr 2020

French scientists suggest nicotinic agonists could treat COVID-19

Contrary to the warnings issued by health agencies worldwide against cigarette smoking amid the coronavirus disease (COVID-19), a new paper suggests the possibility that nicotine, a component of tobacco, could prevent coronavirus infection.

28 Apr 2020

Study shows why people with certain heart diseases may be more susceptible to COVID-19

People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown.

28 Apr 2020

Gut microbiota could predict severity of COVID-19

The COVID-19 pandemic is spreading to every corner of the world. But not everyone is falling sick at the same rate. A new study published on the preprint server medRxiv in April 2020 suggests that the composition of the gut microbiome could partially explain the difference in susceptibility. This adds a new dimension to what is currently known about the disease.

27 Apr 2020

SARS-CoV-2 readily infects human intestinal cells in a laboratory model

A new Dutch study available on bioRxiv uses differentiated human small intestinal organoids in vitro to demonstrate that intestinal epithelium supports the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and elicits a strong generic immune response.

27 Apr 2020

SARS-CoV-2 spike protein discovery could pave way for COVID-19 vaccine

Researchers at the Indian Institute of Technology, Guwahati, have made an important discovery about a viral fusion protein found on the surface of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could help researchers develop a vaccine.

27 Apr 2020

Investigational drug may hold benefit for patients with lung and ovarian cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.

27 Apr 2020

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

27 Apr 2020

Rice University looks to ‘trap and zap’ SARS-CoV-2 in wastewater

A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.

27 Apr 2020

Goblet cells in the human nasal passage may play key role in enabling COVID-19 infections

Two significant international studies involving hundreds of scientists, including a human geneticist at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that specific cells in the human nasal passage shaped like a champagne glass, known as goblet cells, may play a significant role in enabling COVID-19 infections.

24 Apr 2020